Experience of use of 2-ethyl-6-methyl-3-hydroxypyridine succinate in complex therapy of stable angina

2019 ◽  
Vol 0 (3) ◽  
pp. 52-59
Author(s):  
N. D. Oryshchyn ◽  
S. S. Pavlyk ◽  
O. Y. Soroka ◽  
M. V. Cherkavska ◽  
R. Y. Romanyk
2021 ◽  
Vol 2021 (2) ◽  
pp. 118-123
Author(s):  
O.M. Korzh ◽  

The study of the clinical efficacy and safety of the dietary supplement L-Quercet as part of the complex therapy of patients with coronary artery disease with stable angina of II functional class, taking into account their effect on the clinical course of the disease, exercise tolerance and functional state of the endothelium. It has been shown that the inclusion of L-Quercet in the complex therapy in patients with stable angina leads to an improvement in the clinical course of angina pectoris, allows to significantly increase exercise tolerance and the quality of life of patients. The use of L-Quercet improves the indicators of endothelial function according to the results of the cuff test, which is one of the main factors in the prevention of the development and progression of atherosclerosis and coronary artery disease, and also causes an increase in the effectiveness of antianginal pharmacotherapy


2019 ◽  
Vol 6 ◽  
pp. 9-14
Author(s):  
Denys Volynskyi ◽  
Ihor Vakaliuk

Coronary artery disease (CAD) remains one of the leading causes of mortality and disability in Ukraine. Arterial hypertension (AH) is one of the most common diseases and a leading risk factor for coronary artery disease. The aim of the work is to evaluate the antianginal activity of meldonium in the complex therapy in patients with CAD with stable angina and concomitant AH. Materials and methods. The study included 82 patients with CAD, stable angina pectoris II–III functional class, including 52 patients with concomitant AH stage II. The patients were divided into 2 groups. Patients in group 1 were prescribed meldonium at a dose of 750 mg/d for 2 months in addition to basic therapy for the underlying disease. Patients in group 2 continued basic antianginal, disaggregant, hypolipidemic therapy. Results. The use of meldonium led to a decrease in the frequency of angina attacks and the need for nitroglycerin. From the 1st month of therapy and up to 2 months treatment decreased it consumption by 63 and 82.3 % respectively. Adding meldonium to basic therapy led to a likely reduction in shortness of breath, episodes of palpitations, tinnitus, and headache. In all patients, after the treatment, an increase in exercise tolerance was observed, which was more pronounced in the group where patients were receiving meldonium. In the group of patients receiving meldonium, normalisation of blood pressure was faster and more pronounced. Conclusions. Meldonium has antianginal activity, which is manifested by an increase in the physical tolerance of patients, a decrease in the frequency of angina attacks, the need for sublingual nitroglycerin intake and improvement in the well-being of patients. Additional use of meldonium promotes faster and better normalization of blood pressure. The use of meldonium in the complex therapy of patients with stable angina and concomitant AH allows to increase the effectiveness of traditional antianginal therapy and to improve the quality of life of such patients.


2012 ◽  
Vol 11 (1) ◽  
pp. 96-103 ◽  
Author(s):  
V. P. Mikhin ◽  
Yu. M. Pozdnyakov ◽  
F. E. Khlebodarov ◽  
O. N. Koltsova

The review discusses the benefits and various practical aspects of the new cardioprotector mildronate use in cardiology. The latest evidence on the mildronate role in complex therapy of patients with stable angina, or patients in the rehabilitation period after myocardial infarction, is summarised.


2009 ◽  
Vol 39 (18) ◽  
pp. 18
Author(s):  
MITCHEL L. ZOLER
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document